Verubulin (Synonyms: MPC 6827)

Name: Verubulin
Brand: MedChemExpress
SKU: HY-14907
Rating: 4.5 (0 reviews)

Cat. No.: HY-14907 Purity: 99.85%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Verubulin (MPC-6827) is a highly potent and broad-spectrum microtubule blocker. Verubulin has antitumor activity against breast cancer, melanoma, and ovarian cancer. Verubulin can be used in non-small cell lung cancer research.

For research use only. We do not sell to patients.

Verubulin Chemical Structure

CAS No. : 827031-83-4

Size	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
25 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
200 mg	Get quote
500 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 Customer Validation

Other Forms of Verubulin:

Verubulin hydrochloride In-stock

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target

Microtubule^[1]

Cellular Effect

Cell Line	Type	Value	Description	References
A-375	IC₅₀	0.7 1 Compound: Verubulin	Antiproliferative activity against human A-375 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTS assay Antiproliferative activity against human A-375 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTS assay	[PMID: 34406768]
A-375	IC₅₀	0.7 1 Compound: Verubulin	Antiproliferative activity against human A-375 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTS assay Antiproliferative activity against human A-375 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTS assay	[PMID: 34406768]
A549	IC₅₀	0.005 3 Compound: MPC6827	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 30093295]
A-431	IC₅₀	0.9 1 Compound: 1	Cytotoxicity against human A-431 cells assessed as reduction in cell viability by Sulforhodamine B assay Cytotoxicity against human A-431 cells assessed as reduction in cell viability by Sulforhodamine B assay	[PMID: 33647840]
A549	IC₅₀	0.004 3 Compound: MPC-6827	Antiproliferative activity against human A549 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human A549 cells incubated for 48 hrs by MTT assay	[PMID: 29673981]
A375/TxR	IC₅₀	0.7 1 Compound: Verubulin	Antiproliferative activity against human A375/TxR cells assessed as inhibition of cell proliferation measured after 72 hrs by MTS assay Antiproliferative activity against human A375/TxR cells assessed as inhibition of cell proliferation measured after 72 hrs by MTS assay	[PMID: 34406768]
A375/TxR	IC₅₀	0.7 1 Compound: Verubulin	Antiproliferative activity against human A375/TxR cells assessed as inhibition of cell proliferation measured after 72 hrs by MTS assay Antiproliferative activity against human A375/TxR cells assessed as inhibition of cell proliferation measured after 72 hrs by MTS assay	[PMID: 34406768]
A-431	IC₅₀	0.9 1 Compound: 1	Cytotoxicity against human A-431 cells assessed as reduction in cell viability by Sulforhodamine B assay Cytotoxicity against human A-431 cells assessed as reduction in cell viability by Sulforhodamine B assay	[PMID: 33647840]
A549	IC₅₀	0.003 3 Compound: EP128495	Growth inhibition of human A549 cells after 48 hrs by MTT assay Growth inhibition of human A549 cells after 48 hrs by MTT assay	[PMID: 29509413]
A549	IC₅₀	0.003 3 Compound: EP128495	Growth inhibition of human A549 cells after 48 hrs by MTT assay Growth inhibition of human A549 cells after 48 hrs by MTT assay	[PMID: 29509413]
A549	IC₅₀	0.003 3 Compound: EP128495	Growth inhibition of human A549 cells after 48 hrs by MTT assay Growth inhibition of human A549 cells after 48 hrs by MTT assay	[PMID: 29509413]
A549/CDDP	IC₅₀	0.009 3 Compound: EP128495	Growth inhibition of human A549/CDDP cells after 48 hrs by MTT assay Growth inhibition of human A549/CDDP cells after 48 hrs by MTT assay	[PMID: 29509413]
A549	IC₅₀	0.004 3 Compound: MPC-6827	Antiproliferative activity against human A549 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human A549 cells incubated for 48 hrs by MTT assay	[PMID: 29673981]
A549	IC₅₀	0.004 3 Compound: MPC-6827	Antiproliferative activity against human A549 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human A549 cells incubated for 48 hrs by MTT assay	[PMID: 29673981]
A-375	IC₅₀	0.7 1 Compound: Verubulin	Antiproliferative activity against human A-375 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTS assay Antiproliferative activity against human A-375 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTS assay	[PMID: 34406768]
A375/TxR	IC₅₀	0.7 1 Compound: Verubulin	Antiproliferative activity against human A375/TxR cells assessed as inhibition of cell proliferation measured after 72 hrs by MTS assay Antiproliferative activity against human A375/TxR cells assessed as inhibition of cell proliferation measured after 72 hrs by MTS assay	[PMID: 34406768]
A549	IC₅₀	0.005 3 Compound: MPC6827	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 30093295]
A549	IC₅₀	0.005 3 Compound: MPC6827	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 30093295]
A549/CDDP	IC₅₀	0.009 3 Compound: EP128495	Growth inhibition of human A549/CDDP cells after 48 hrs by MTT assay Growth inhibition of human A549/CDDP cells after 48 hrs by MTT assay	[PMID: 29509413]
BJ	IC₅₀	0.015 3 Compound: EP128495	Antiproliferative activity against human BJ cells after 48 hrs by MTT assay Antiproliferative activity against human BJ cells after 48 hrs by MTT assay	[PMID: 29509413]
A549/CDDP	IC₅₀	0.009 3 Compound: EP128495	Growth inhibition of human A549/CDDP cells after 48 hrs by MTT assay Growth inhibition of human A549/CDDP cells after 48 hrs by MTT assay	[PMID: 29509413]
BJ	IC₅₀	0.015 3 Compound: EP128495	Antiproliferative activity against human BJ cells after 48 hrs by MTT assay Antiproliferative activity against human BJ cells after 48 hrs by MTT assay	[PMID: 29509413]
BJ	IC₅₀	0.015 3 Compound: EP128495	Antiproliferative activity against human BJ cells after 48 hrs by MTT assay Antiproliferative activity against human BJ cells after 48 hrs by MTT assay	[PMID: 29509413]
A-431	IC₅₀	0.9 1 Compound: 1	Cytotoxicity against human A-431 cells assessed as reduction in cell viability by Sulforhodamine B assay Cytotoxicity against human A-431 cells assessed as reduction in cell viability by Sulforhodamine B assay	[PMID: 33647840]
M14	IC₅₀	1 1 Compound: Verubulin	Antiproliferative activity against human M14 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTS assay Antiproliferative activity against human M14 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTS assay	[PMID: 34406768]
HCT-116	EC₅₀	0.003 3 Compound: 6h, EP128495,MPC-6827, azixa	Induction of apoptosis in human HCT116 cells assessed as caspase activation after 24 hrs by HTS assay Induction of apoptosis in human HCT116 cells assessed as caspase activation after 24 hrs by HTS assay	[PMID: 19296653]
HCT-116	EC₅₀	0.003 3 Compound: 6h, EP128495,MPC-6827, azixa	Induction of apoptosis in human HCT116 cells assessed as caspase activation after 24 hrs by HTS assay Induction of apoptosis in human HCT116 cells assessed as caspase activation after 24 hrs by HTS assay	[PMID: 19296653]
HCT-116	IC₅₀	0.004 3 Compound: EP128495	Growth inhibition of human HCT116 cells after 48 hrs by MTT assay Growth inhibition of human HCT116 cells after 48 hrs by MTT assay	[PMID: 29509413]
HCT-116	GI₅₀	0.006 3 Compound: 6h, EP128495,MPC-6827, azixa	Growth inhibition of human HCT116 cells after 48 hrs by celltiter assay Growth inhibition of human HCT116 cells after 48 hrs by celltiter assay	[PMID: 19296653]
HeLa	IC₅₀	1.5 1 Compound: 1	Cytotoxicity against human HeLa cells over expressing WT-beta3 assessed as reduction in cell viability by Sulforhodamine B assay Cytotoxicity against human HeLa cells over expressing WT-beta3 assessed as reduction in cell viability by Sulforhodamine B assay	[PMID: 33647840]
MDA-MB-435	IC₅₀	1.7 1 Compound: 1	Antiproliferative activity against human MDA-MB-435 cells assessed as reduction in cell viability by Sulforhodamine B assay Antiproliferative activity against human MDA-MB-435 cells assessed as reduction in cell viability by Sulforhodamine B assay	[PMID: 33647840]
HCT-116	IC₅₀	0.005 3 Compound: MPC-6827	Antiproliferative activity against human HCT116 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells incubated for 48 hrs by MTT assay	[PMID: 29673981]
HCT-116	IC₅₀	0.004 3 Compound: EP128495	Growth inhibition of human HCT116 cells after 48 hrs by MTT assay Growth inhibition of human HCT116 cells after 48 hrs by MTT assay	[PMID: 29509413]
HCT-116	IC₅₀	0.005 3 Compound: MPC-6827	Antiproliferative activity against human HCT116 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells incubated for 48 hrs by MTT assay	[PMID: 29673981]
HeLa	IC₅₀	2 1 Compound: 1	Cytotoxicity against human HeLa cells assessed as reduction in cell viability by Sulforhodamine B assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability by Sulforhodamine B assay	[PMID: 33647840]
HCT-116	GI₅₀	0.006 3 Compound: 6h, EP128495,MPC-6827, azixa	Growth inhibition of human HCT116 cells after 48 hrs by celltiter assay Growth inhibition of human HCT116 cells after 48 hrs by celltiter assay	[PMID: 19296653]
HCT-116	IC₅₀	0.009 3 Compound: MPC6827	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 30093295]
HCT-116	IC₅₀	0.009 3 Compound: MPC6827	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 30093295]
SK-OV-3	IC₅₀	2.2 1 Compound: 1	Cytotoxicity against human SK-OV-3 cells assessed as reduction in cell viability by Sulforhodamine B assay Cytotoxicity against human SK-OV-3 cells assessed as reduction in cell viability by Sulforhodamine B assay	[PMID: 33647840]
HCT-116	IC₅₀	4.3 1 Compound: 5; MPC-6827	Antiproliferative activity against human HCT116 cells after 24 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 24 hrs by MTT assay	[PMID: 27213819]
SK-OV-3	IC₅₀	2.6 1 Compound: 1	Cytotoxicity against human SK-OV-3 cells over expressing MDR1-6/6 assessed as reduction in cell viability by Sulforhodamine B assay Cytotoxicity against human SK-OV-3 cells over expressing MDR1-6/6 assessed as reduction in cell viability by Sulforhodamine B assay	[PMID: 33647840]
HCT-116	IC₅₀	4.3 1 Compound: 5; MPC-6827	Antiproliferative activity against human HCT116 cells after 24 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 24 hrs by MTT assay	[PMID: 27213819]
HeLa	IC₅₀	0.005 3 Compound: EP128495	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 29509413]
U-251	IC₅₀	2.8 1 Compound: 1	Cytotoxicity against human U-251 cells assessed as reduction in cell viability by Sulforhodamine B assay Cytotoxicity against human U-251 cells assessed as reduction in cell viability by Sulforhodamine B assay	[PMID: 33647840]
HeLa	IC₅₀	0.005 3 Compound: EP128495	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 29509413]
HeLa	IC₅₀	0.006 3 Compound: MPC-6827	Antiproliferative activity against human HeLa cells incubated for 48 hrs by MTT assay Antiproliferative activity against human HeLa cells incubated for 48 hrs by MTT assay	[PMID: 29673981]
HeLa	IC₅₀	0.006 3 Compound: MPC-6827	Antiproliferative activity against human HeLa cells incubated for 48 hrs by MTT assay Antiproliferative activity against human HeLa cells incubated for 48 hrs by MTT assay	[PMID: 29673981]
SK-OV-3	IC₅₀	3.2 1 Compound: 5; MPC-6827	Antiproliferative activity against human SKOV3 cells after 24 hrs by MTT assay Antiproliferative activity against human SKOV3 cells after 24 hrs by MTT assay	[PMID: 27213819]
HeLa	IC₅₀	0.007 3 Compound: MPC6827	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 30093295]
HCT-116	IC₅₀	4.3 1 Compound: 5; MPC-6827	Antiproliferative activity against human HCT116 cells after 24 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 24 hrs by MTT assay	[PMID: 27213819]
HeLa	IC₅₀	0.007 3 Compound: MPC6827	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 30093295]
HeLa	IC₅₀	1.5 1 Compound: 1	Cytotoxicity against human HeLa cells over expressing WT-beta3 assessed as reduction in cell viability by Sulforhodamine B assay Cytotoxicity against human HeLa cells over expressing WT-beta3 assessed as reduction in cell viability by Sulforhodamine B assay	[PMID: 33647840]
HepG2	IC₅₀	4.6 1 Compound: 5; MPC-6827	Antiproliferative activity against human HepG2 cells after 24 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 24 hrs by MTT assay	[PMID: 27213819]
HeLa	IC₅₀	1.5 1 Compound: 1	Cytotoxicity against human HeLa cells over expressing WT-beta3 assessed as reduction in cell viability by Sulforhodamine B assay Cytotoxicity against human HeLa cells over expressing WT-beta3 assessed as reduction in cell viability by Sulforhodamine B assay	[PMID: 33647840]
HeLa	IC₅₀	2 1 Compound: 1	Cytotoxicity against human HeLa cells assessed as reduction in cell viability by Sulforhodamine B assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability by Sulforhodamine B assay	[PMID: 33647840]
HeLa	IC₅₀	2 1 Compound: 1	Cytotoxicity against human HeLa cells assessed as reduction in cell viability by Sulforhodamine B assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability by Sulforhodamine B assay	[PMID: 33647840]
HCT-116	EC₅₀	0.003 3 Compound: 6h, EP128495,MPC-6827, azixa	Induction of apoptosis in human HCT116 cells assessed as caspase activation after 24 hrs by HTS assay Induction of apoptosis in human HCT116 cells assessed as caspase activation after 24 hrs by HTS assay	[PMID: 19296653]
HepG2	IC₅₀	0.005 3 Compound: EP128495	Growth inhibition of human HepG2 cells after 48 hrs by MTT assay Growth inhibition of human HepG2 cells after 48 hrs by MTT assay	[PMID: 29509413]
HepG2	IC₅₀	0.005 3 Compound: MPC-6827	Antiproliferative activity against human HepG2 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells incubated for 48 hrs by MTT assay	[PMID: 29673981]
HCT-116	GI₅₀	0.006 3 Compound: 6h, EP128495,MPC-6827, azixa	Growth inhibition of human HCT116 cells after 48 hrs by celltiter assay Growth inhibition of human HCT116 cells after 48 hrs by celltiter assay	[PMID: 19296653]
HepG2	IC₅₀	0.005 3 Compound: MPC-6827	Antiproliferative activity against human HepG2 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells incubated for 48 hrs by MTT assay	[PMID: 29673981]
HepG2	IC₅₀	0.005 3 Compound: EP128495	Growth inhibition of human HepG2 cells after 48 hrs by MTT assay Growth inhibition of human HepG2 cells after 48 hrs by MTT assay	[PMID: 29509413]
HCT-116	IC₅₀	0.009 3 Compound: MPC6827	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 30093295]
HCT-116	IC₅₀	0.005 3 Compound: MPC-6827	Antiproliferative activity against human HCT116 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells incubated for 48 hrs by MTT assay	[PMID: 29673981]
HepG2	IC₅₀	0.006 3 Compound: MPC6827	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 30093295]
HepG2	IC₅₀	0.006 3 Compound: MPC6827	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 30093295]
HepG2	IC₅₀	4.6 1 Compound: 5; MPC-6827	Antiproliferative activity against human HepG2 cells after 24 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 24 hrs by MTT assay	[PMID: 27213819]
HCT-116	IC₅₀	0.004 3 Compound: EP128495	Growth inhibition of human HCT116 cells after 48 hrs by MTT assay Growth inhibition of human HCT116 cells after 48 hrs by MTT assay	[PMID: 29509413]
HepG2	IC₅₀	4.6 1 Compound: 5; MPC-6827	Antiproliferative activity against human HepG2 cells after 24 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 24 hrs by MTT assay	[PMID: 27213819]
L02	IC₅₀	0.013 3 Compound: EP128495	Antiproliferative activity against human LO2 cells after 48 hrs by MTT assay Antiproliferative activity against human LO2 cells after 48 hrs by MTT assay	[PMID: 29509413]
HeLa	IC₅₀	0.005 3 Compound: EP128495	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 29509413]
LoVo	IC₅₀	0.008 3 Compound: EP128495	Growth inhibition of human LoVo cells after 48 hrs by MTT assay Growth inhibition of human LoVo cells after 48 hrs by MTT assay	[PMID: 29509413]
HeLa	IC₅₀	0.007 3 Compound: MPC6827	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 30093295]
L02	IC₅₀	0.013 3 Compound: EP128495	Antiproliferative activity against human LO2 cells after 48 hrs by MTT assay Antiproliferative activity against human LO2 cells after 48 hrs by MTT assay	[PMID: 29509413]
HeLa	IC₅₀	0.006 3 Compound: MPC-6827	Antiproliferative activity against human HeLa cells incubated for 48 hrs by MTT assay Antiproliferative activity against human HeLa cells incubated for 48 hrs by MTT assay	[PMID: 29673981]
M14	IC₅₀	1 1 Compound: Verubulin	Antiproliferative activity against human M14 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTS assay Antiproliferative activity against human M14 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTS assay	[PMID: 34406768]
MCF7	IC₅₀	0.011 3 Compound: EP128495	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 29509413]
HepG2	IC₅₀	0.006 3 Compound: MPC6827	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 30093295]
LoVo	IC₅₀	0.008 3 Compound: EP128495	Growth inhibition of human LoVo cells after 48 hrs by MTT assay Growth inhibition of human LoVo cells after 48 hrs by MTT assay	[PMID: 29509413]
M14	IC₅₀	1 1 Compound: Verubulin	Antiproliferative activity against human M14 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTS assay Antiproliferative activity against human M14 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTS assay	[PMID: 34406768]
MDA-MB-231	IC₅₀	0.008 3 Compound: MPC-6827	Antiproliferative activity against human MDA-MB-231 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells incubated for 48 hrs by MTT assay	[PMID: 29673981]
HepG2	IC₅₀	0.005 3 Compound: MPC-6827	Antiproliferative activity against human HepG2 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells incubated for 48 hrs by MTT assay	[PMID: 29673981]
MCF7	IC₅₀	0.011 3 Compound: EP128495	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 29509413]
HepG2	IC₅₀	0.005 3 Compound: EP128495	Growth inhibition of human HepG2 cells after 48 hrs by MTT assay Growth inhibition of human HepG2 cells after 48 hrs by MTT assay	[PMID: 29509413]
MDA-MB-231	IC₅₀	0.008 3 Compound: EP128495	Growth inhibition of human MDA-MB-231 cells after 48 hrs by MTT assay Growth inhibition of human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 29509413]
MDA-MB-435	IC₅₀	1.7 1 Compound: 1	Antiproliferative activity against human MDA-MB-435 cells assessed as reduction in cell viability by Sulforhodamine B assay Antiproliferative activity against human MDA-MB-435 cells assessed as reduction in cell viability by Sulforhodamine B assay	[PMID: 33647840]
L02	IC₅₀	0.013 3 Compound: EP128495	Antiproliferative activity against human LO2 cells after 48 hrs by MTT assay Antiproliferative activity against human LO2 cells after 48 hrs by MTT assay	[PMID: 29509413]
MDA-MB-231	IC₅₀	0.008 3 Compound: EP128495	Growth inhibition of human MDA-MB-231 cells after 48 hrs by MTT assay Growth inhibition of human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 29509413]
LoVo	IC₅₀	0.008 3 Compound: EP128495	Growth inhibition of human LoVo cells after 48 hrs by MTT assay Growth inhibition of human LoVo cells after 48 hrs by MTT assay	[PMID: 29509413]
MGC-803	IC₅₀	0.008 3 Compound: EP128495	Antiproliferative activity against human MGC803 cells after 48 hrs by MTT assay Antiproliferative activity against human MGC803 cells after 48 hrs by MTT assay	[PMID: 29509413]
MDA-MB-231	IC₅₀	0.008 3 Compound: MPC-6827	Antiproliferative activity against human MDA-MB-231 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells incubated for 48 hrs by MTT assay	[PMID: 29673981]
NCI-H1299	EC₅₀	0.006 3 Compound: 1e	Induction of apoptosis in human H1299 cells assessed as caspase activation after 48 hrs by HTS assay Induction of apoptosis in human H1299 cells assessed as caspase activation after 48 hrs by HTS assay	[PMID: 19464890]
MCF7	IC₅₀	0.011 3 Compound: EP128495	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 29509413]
MDA-MB-435	IC₅₀	1.7 1 Compound: 1	Antiproliferative activity against human MDA-MB-435 cells assessed as reduction in cell viability by Sulforhodamine B assay Antiproliferative activity against human MDA-MB-435 cells assessed as reduction in cell viability by Sulforhodamine B assay	[PMID: 33647840]
RKO	IC₅₀	0.003 3 Compound: EP128495	Growth inhibition of human RKO cells after 48 hrs by MTT assay Growth inhibition of human RKO cells after 48 hrs by MTT assay	[PMID: 29509413]
MDA-MB-231	IC₅₀	0.008 3 Compound: MPC-6827	Antiproliferative activity against human MDA-MB-231 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells incubated for 48 hrs by MTT assay	[PMID: 29673981]
MGC-803	IC₅₀	0.008 3 Compound: EP128495	Antiproliferative activity against human MGC803 cells after 48 hrs by MTT assay Antiproliferative activity against human MGC803 cells after 48 hrs by MTT assay	[PMID: 29509413]
NCI-H1299	EC₅₀	0.006 3 Compound: 1e	Induction of apoptosis in human H1299 cells assessed as caspase activation after 48 hrs by HTS assay Induction of apoptosis in human H1299 cells assessed as caspase activation after 48 hrs by HTS assay	[PMID: 19464890]
MDA-MB-231	IC₅₀	0.008 3 Compound: EP128495	Growth inhibition of human MDA-MB-231 cells after 48 hrs by MTT assay Growth inhibition of human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 29509413]
RKO	IC₅₀	0.005 3 Compound: MPC6827	Antiproliferative activity against human RKO cells after 48 hrs by MTT assay Antiproliferative activity against human RKO cells after 48 hrs by MTT assay	[PMID: 30093295]
NCI-H1299	EC₅₀	0.007 3 Compound: 1g	Induction of apoptosis in human H1299 cells assessed as caspase activation Induction of apoptosis in human H1299 cells assessed as caspase activation	[PMID: 20188546]
SK-OV-3	IC₅₀	2.2 1 Compound: 1	Cytotoxicity against human SK-OV-3 cells assessed as reduction in cell viability by Sulforhodamine B assay Cytotoxicity against human SK-OV-3 cells assessed as reduction in cell viability by Sulforhodamine B assay	[PMID: 33647840]
MGC-803	IC₅₀	0.008 3 Compound: EP128495	Antiproliferative activity against human MGC803 cells after 48 hrs by MTT assay Antiproliferative activity against human MGC803 cells after 48 hrs by MTT assay	[PMID: 29509413]
SK-OV-3	IC₅₀	2.6 1 Compound: 1	Cytotoxicity against human SK-OV-3 cells over expressing MDR1-6/6 assessed as reduction in cell viability by Sulforhodamine B assay Cytotoxicity against human SK-OV-3 cells over expressing MDR1-6/6 assessed as reduction in cell viability by Sulforhodamine B assay	[PMID: 33647840]
RKO	IC₅₀	0.003 3 Compound: EP128495	Growth inhibition of human RKO cells after 48 hrs by MTT assay Growth inhibition of human RKO cells after 48 hrs by MTT assay	[PMID: 29509413]
NCI-H1299	EC₅₀	0.007 3 Compound: 1g	Induction of apoptosis in human H1299 cells assessed as caspase activation Induction of apoptosis in human H1299 cells assessed as caspase activation	[PMID: 20188546]
RKO	IC₅₀	0.005 3 Compound: MPC6827	Antiproliferative activity against human RKO cells after 48 hrs by MTT assay Antiproliferative activity against human RKO cells after 48 hrs by MTT assay	[PMID: 30093295]
SK-OV-3	IC₅₀	3.2 1 Compound: 5; MPC-6827	Antiproliferative activity against human SKOV3 cells after 24 hrs by MTT assay Antiproliferative activity against human SKOV3 cells after 24 hrs by MTT assay	[PMID: 27213819]
NCI-H1299	EC₅₀	0.006 3 Compound: 1e	Induction of apoptosis in human H1299 cells assessed as caspase activation after 48 hrs by HTS assay Induction of apoptosis in human H1299 cells assessed as caspase activation after 48 hrs by HTS assay	[PMID: 19464890]
RKO	IC₅₀	0.005 3 Compound: MPC6827	Antiproliferative activity against human RKO cells after 48 hrs by MTT assay Antiproliferative activity against human RKO cells after 48 hrs by MTT assay	[PMID: 30093295]
SNU-398	EC₅₀	0.002 3 Compound: 6h, EP128495,MPC-6827, azixa	Induction of apoptosis in human SNU398 cells assessed as caspase activation after 24 hrs by HTS assay Induction of apoptosis in human SNU398 cells assessed as caspase activation after 24 hrs by HTS assay	[PMID: 19296653]
SK-OV-3	IC₅₀	2.2 1 Compound: 1	Cytotoxicity against human SK-OV-3 cells assessed as reduction in cell viability by Sulforhodamine B assay Cytotoxicity against human SK-OV-3 cells assessed as reduction in cell viability by Sulforhodamine B assay	[PMID: 33647840]
RKO	IC₅₀	0.003 3 Compound: EP128495	Growth inhibition of human RKO cells after 48 hrs by MTT assay Growth inhibition of human RKO cells after 48 hrs by MTT assay	[PMID: 29509413]
SNU-398	GI₅₀	0.003 3 Compound: 6h, EP128495,MPC-6827, azixa	Growth inhibition of human SNU398 cells after 48 hrs by celltiter assay Growth inhibition of human SNU398 cells after 48 hrs by celltiter assay	[PMID: 19296653]
SK-OV-3	IC₅₀	2.6 1 Compound: 1	Cytotoxicity against human SK-OV-3 cells over expressing MDR1-6/6 assessed as reduction in cell viability by Sulforhodamine B assay Cytotoxicity against human SK-OV-3 cells over expressing MDR1-6/6 assessed as reduction in cell viability by Sulforhodamine B assay	[PMID: 33647840]
SNU-398	EC₅₀	0.002 3 Compound: 6h, EP128495,MPC-6827, azixa	Induction of apoptosis in human SNU398 cells assessed as caspase activation after 24 hrs by HTS assay Induction of apoptosis in human SNU398 cells assessed as caspase activation after 24 hrs by HTS assay	[PMID: 19296653]
T47D	EC₅₀	0.002 3 Compound: 6h, EP128495,MPC-6827, azixa	Induction of apoptosis in human T47D cells assessed as caspase activation after 24 hrs by HTS assay Induction of apoptosis in human T47D cells assessed as caspase activation after 24 hrs by HTS assay	[PMID: 19296653]
SK-OV-3	IC₅₀	3.2 1 Compound: 5; MPC-6827	Antiproliferative activity against human SKOV3 cells after 24 hrs by MTT assay Antiproliferative activity against human SKOV3 cells after 24 hrs by MTT assay	[PMID: 27213819]
SNU-398	EC₅₀	0.002 3 Compound: 6h, EP128495,MPC-6827, azixa	Induction of apoptosis in human SNU398 cells assessed as caspase activation after 24 hrs by HTS assay Induction of apoptosis in human SNU398 cells assessed as caspase activation after 24 hrs by HTS assay	[PMID: 19296653]
T47D	EC₅₀	0.002 3 Compound: 1e	Induction of apoptosis in human T47D cells assessed as caspase activation after 48 hrs by HTS assay Induction of apoptosis in human T47D cells assessed as caspase activation after 48 hrs by HTS assay	[PMID: 19464890]
SNU-398	GI₅₀	0.003 3 Compound: 6h, EP128495,MPC-6827, azixa	Growth inhibition of human SNU398 cells after 48 hrs by celltiter assay Growth inhibition of human SNU398 cells after 48 hrs by celltiter assay	[PMID: 19296653]
T47D	EC₅₀	0.002 3 Compound: 1g	Induction of apoptosis in human T47D cells assessed as caspase activation Induction of apoptosis in human T47D cells assessed as caspase activation	[PMID: 20188546]
T47D	GI₅₀	0.006 3 Compound: 6h, EP128495,MPC-6827, azixa	Growth inhibition of human T47D cells after 48 hrs by celltiter assay Growth inhibition of human T47D cells after 48 hrs by celltiter assay	[PMID: 19296653]
SNU-398	GI₅₀	0.003 3 Compound: 6h, EP128495,MPC-6827, azixa	Growth inhibition of human SNU398 cells after 48 hrs by celltiter assay Growth inhibition of human SNU398 cells after 48 hrs by celltiter assay	[PMID: 19296653]
U-251	IC₅₀	2.8 1 Compound: 1	Cytotoxicity against human U-251 cells assessed as reduction in cell viability by Sulforhodamine B assay Cytotoxicity against human U-251 cells assessed as reduction in cell viability by Sulforhodamine B assay	[PMID: 33647840]
T47D	EC₅₀	0.002 3 Compound: 6h, EP128495,MPC-6827, azixa	Induction of apoptosis in human T47D cells assessed as caspase activation after 24 hrs by HTS assay Induction of apoptosis in human T47D cells assessed as caspase activation after 24 hrs by HTS assay	[PMID: 19296653]
T47D	EC₅₀	0.002 3 Compound: 1e	Induction of apoptosis in human T47D cells assessed as caspase activation after 48 hrs by HTS assay Induction of apoptosis in human T47D cells assessed as caspase activation after 48 hrs by HTS assay	[PMID: 19464890]
T47D	GI₅₀	0.006 3 Compound: 6h, EP128495,MPC-6827, azixa	Growth inhibition of human T47D cells after 48 hrs by celltiter assay Growth inhibition of human T47D cells after 48 hrs by celltiter assay	[PMID: 19296653]
T47D	EC₅₀	0.002 3 Compound: 1e	Induction of apoptosis in human T47D cells assessed as caspase activation after 48 hrs by HTS assay Induction of apoptosis in human T47D cells assessed as caspase activation after 48 hrs by HTS assay	[PMID: 19464890]
T47D	EC₅₀	0.002 3 Compound: 1g	Induction of apoptosis in human T47D cells assessed as caspase activation Induction of apoptosis in human T47D cells assessed as caspase activation	[PMID: 20188546]
T47D	EC₅₀	0.002 3 Compound: 6h, EP128495,MPC-6827, azixa	Induction of apoptosis in human T47D cells assessed as caspase activation after 24 hrs by HTS assay Induction of apoptosis in human T47D cells assessed as caspase activation after 24 hrs by HTS assay	[PMID: 19296653]
T47D	GI₅₀	0.006 3 Compound: 6h, EP128495,MPC-6827, azixa	Growth inhibition of human T47D cells after 48 hrs by celltiter assay Growth inhibition of human T47D cells after 48 hrs by celltiter assay	[PMID: 19296653]
U-251	IC₅₀	2.8 1 Compound: 1	Cytotoxicity against human U-251 cells assessed as reduction in cell viability by Sulforhodamine B assay Cytotoxicity against human U-251 cells assessed as reduction in cell viability by Sulforhodamine B assay	[PMID: 33647840]

In Vitro

Verubulin (10 nM; 1-3 h) rapidly disrupts microtubule formation in human A549 non-small-cell lung carcinoma cells^[2].
Verubulin inhibits the growth of MCF-7 cells with an IC₅₀ value of 2.1 nM^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Verubulin (7.5 mg/kg; i.v.; once or 1 mg/kg; i.v.; 5 days) induces tumor growth inhibition in B16 mouse melanoma model^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Athymic mice (nu/nu), B16 mouse melanoma or OVCAR3 human ovarian cancer cell-implanted subcutaneous xenograft models^[3]
Dosage:	1 mg/kg, 7.5 mg/kg (B16); 2.5, 5 or 10 mg/kg (OVCAR-3)
Administration:	In the B16 study, 7.5 mg/kg was dosed intravenously (i.v.) once, or 1 mg/kg was dosed daily for five days. In the OVCAR-3 study, 5 mg/kg was dosed i.v. once, or 2.5-10 mg/kg/day was dosed intraperitoneally (i.p.) with an Alzet mini-pump for one day.
Result:	Resulted in 72% tumor growth inhibition (TGI) on day 7 relative to vehicle at 7.5 mg/kg dose (in the B16 model). Resulted in only 22% TGI (at the 1 mg/kg daily dosing for five days) (in the B16 model). Did not result in inhibition of xenograft tumor growth relative to vehicle at day 17 when administered intraperitoneally at a dose of 2.5 mg/kg for 24 hours (in the OVCAR-3 model). Resulted in 50% regression at single 5 mg/kg dose (i.v.) (in the OVCAR-3 model). Showed median time to tumor volume of 1500 mm³: 28.5 days (2.5 mg/kg/day i.p. group); > 39 days (5 mg/kg i.v. group).

Molecular Weight

279.34

Formula

C₁₇H₁₇N₃O

CAS No.

827031-83-4

Appearance

Solid

Color

Light yellow to yellow

SMILES

CC1=NC(N(C2=CC=C(OC)C=C2)C)=C3C=CC=CC3=N1

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (357.99 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.5799 mL	17.8993 mL	35.7987 mL
5 mM	0.7160 mL	3.5799 mL	7.1597 mL
10 mM	0.3580 mL	1.7899 mL	3.5799 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (7.45 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (7.45 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.08 mg/mL (7.45 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.85%

Select Batch:

Data Sheet (276 KB) SDS (393 KB)

COA (252 KB) HNMR (171 KB) LCMS (102 KB)

Handling Instructions (2659 KB)

References

[1]. Kasibhatla S, et al. MPC-6827: a small-molecule inhibitor of microtubule formation that is not a substrate for multidrug resistance pumps. Cancer Res. 2007 Jun 15;67(12):5865-71. [Content Brief]

[2]. Kasibhatla S, et al. MPC-6827: a small-molecule inhibitor of microtubule formation that is not a substrate for multidrug resistance pumps. Cancer Res. 2007 Jun 15;67(12):5865-71. [Content Brief]

[3]. Jones J T, et al. Comparison of MPC-6827 activity in xenograft models with different dosing schedules. Journal of Clinical Oncology, 2011, 29(15_suppl): e13080-e13080.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	3.5799 mL	17.8993 mL	35.7987 mL	89.4967 mL
	5 mM	0.7160 mL	3.5799 mL	7.1597 mL	17.8993 mL
	10 mM	0.3580 mL	1.7899 mL	3.5799 mL	8.9497 mL
	15 mM	0.2387 mL	1.1933 mL	2.3866 mL	5.9664 mL
	20 mM	0.1790 mL	0.8950 mL	1.7899 mL	4.4748 mL
	25 mM	0.1432 mL	0.7160 mL	1.4319 mL	3.5799 mL
	30 mM	0.1193 mL	0.5966 mL	1.1933 mL	2.9832 mL
	40 mM	0.0895 mL	0.4475 mL	0.8950 mL	2.2374 mL
	50 mM	0.0716 mL	0.3580 mL	0.7160 mL	1.7899 mL
	60 mM	0.0597 mL	0.2983 mL	0.5966 mL	1.4916 mL
	80 mM	0.0447 mL	0.2237 mL	0.4475 mL	1.1187 mL
	100 mM	0.0358 mL	0.1790 mL	0.3580 mL	0.8950 mL

Verubulin Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Verubulin827031-83-4MPC 6827MPC6827MPC-6827Microtubule/TubulinB16OVCAR-3melanomaovarian cancerMCF-7A549Inhibitorinhibitorinhibit

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Product Name			Requested Quantity *
Applicant Name *			Salutation
Email Address *			Phone Number *
Department			Organization Name *
City			State
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Verubulin (Synonyms: MPC 6827)

Customer Review

Other Forms of Verubulin:

Verubulin Related Antibodies

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity

Purity & Documentation

References

Customer Review

Verubulin Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Verubulin Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report